Spots Global Cancer Trial Database for oral cavity squamous cell carcinoma
Every month we try and update this database with for oral cavity squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma | NCT05578170 | Oral Cavity Squ... | Pembrolizumab | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | NCT06084845 | Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biospecimen Col... Carboplatin Chest Radiograp... Cisplatin Computed Tomogr... Image Guided Ra... Intensity-Modul... Magnetic Resona... Positron Emissi... Xevinapant | 18 Years - | Eastern Cooperative Oncology Group | |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | NCT03258554 | Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Pathologic Stag... Squamous Cell C... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph... | Cetuximab Durvalumab Intensity-Modul... Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial | NCT03997643 | Head and Neck C... | Radiotherapy to... Omit radiation ... | 18 Years - | Lawson Health Research Institute | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC | NCT04725396 | Oropharynx Squa... Oral Cavity Squ... | Mandibular Reco... Conventional Ma... | 18 Years - | UNICANCER | |
| Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma | NCT03727594 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 95 Years | University Hospital of Ferrara | ||
| Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC | NCT04725396 | Oropharynx Squa... Oral Cavity Squ... | Mandibular Reco... Conventional Ma... | 18 Years - | UNICANCER | |
| First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | NCT04858269 | Head Neck Cance... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Hypopharynx Squ... Larynx Squamous... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Wake Forest University Health Sciences | |
| Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity | NCT03784066 | Oral Cavity Squ... | Durvalumab Durvalumab + Tr... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | NCT05681039 | Squamous Cell C... Oral Cavity Squ... | Tiragolumab Atezolizumab Standard of Car... Questionnaires Cisplatin Carboplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | NCT02156180 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 90 Years | Queensland Centre of Excellence for Head and Neck Cancer | ||
| Biofeedback Rehabilitation to Improve Speaking and Eating in Public | NCT03650699 | Oral Cavity Squ... | Electropalatogr... | - | University Health Network, Toronto | |
| Biofeedback Rehabilitation to Improve Speaking and Eating in Public | NCT03650699 | Oral Cavity Squ... | Electropalatogr... | - | University Health Network, Toronto | |
| Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience | NCT05950737 | Oral Cavity Squ... | Sentinel node b... | 18 Years - 75 Years | Tata Memorial Hospital | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer | NCT03028766 | Hypopharynx Squ... Oral Cavity Squ... Larynx Cancer | AZD1775 Cisplatin Radiotherapy | 18 Years - 70 Years | University of Birmingham | |
| Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation | NCT03510390 | Head and Neck C... Oral Cavity Squ... | Metformin | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | NCT02923258 | Oral Cavity Squ... | Docetaxel Cisplatin IMRT | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients | NCT03529604 | Oral Cavity Squ... Saliva Altered Precancerous Le... | Saliva sampling ELISA HPLC | - | University of Zagreb | |
| Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | NCT02923258 | Oral Cavity Squ... | Docetaxel Cisplatin IMRT | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | NCT02156180 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 90 Years | Queensland Centre of Excellence for Head and Neck Cancer | ||
| A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma | NCT05749042 | Oral Cavity Squ... | Sintilimab Radiotherapy | 18 Years - 75 Years | China Three Gorges University, Yichang, China | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC | NCT05065346 | Squamous Cell C... Head and Neck S... | Radiation: Diff... | 18 Years - | Alpha Tau Medical LTD. | |
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | NCT03381183 | Squamous Cell C... Squamous Cell C... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Paranasal Sinus... Hypopharynx Squ... Larynx Squamous... | Durvalumab IRX-2 Regimen | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | NCT03618654 | Head and Neck S... Oral Cavity Squ... Oropharyngeal S... | Metformin Durvalumab | 18 Years - | Thomas Jefferson University | |
| Saliva-based Detection of CD44 | NCT03148665 | Oral Cavity Squ... Oropharynx Squa... Squamous Cell C... Squamous Cell C... | OncAlert | 18 Years - | University of California, San Diego | |
| First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | NCT04858269 | Head Neck Cance... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Hypopharynx Squ... Larynx Squamous... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Wake Forest University Health Sciences | |
| Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | NCT02582008 | Current Smoker Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Nasopharyngeal ... Oral Cavity Squ... Oropharyngeal S... | Bupropion Hydro... Laboratory Biom... Nicotine Replac... Quality-of-Life... Questionnaire A... Varenicline | 18 Years - | Wake Forest University Health Sciences | |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | NCT04333537 | Buccal Mucosa S... Floor of Mouth ... Gingival Squamo... Hard Palate Squ... Lip Squamous Ce... Lower Alveolar ... Oral Cavity Squ... Retromolar Trig... Stage I Lip and... Stage II Lip an... Tongue Squamous... Upper Alveolar ... | Computed Tomogr... Imaging Agent Neck Dissection Planar Imaging Sentinel Lymph ... Single Photon E... | 18 Years - | NRG Oncology | |
| Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | NCT03854032 | Lip Oral Cavity Squ... Pharynx Larynx Squamous Cell C... | Nivolumab IDO1 Inhibitor ... Therapeutic Con... Questionnaire A... | 18 Years - | Thomas Jefferson University | |
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | NCT03381183 | Squamous Cell C... Squamous Cell C... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Paranasal Sinus... Hypopharynx Squ... Larynx Squamous... | Durvalumab IRX-2 Regimen | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial | NCT03997643 | Head and Neck C... | Radiotherapy to... Omit radiation ... | 18 Years - | Lawson Health Research Institute | |
| Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients | NCT03529604 | Oral Cavity Squ... Saliva Altered Precancerous Le... | Saliva sampling ELISA HPLC | - | University of Zagreb | |
| First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | NCT04858269 | Head Neck Cance... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Hypopharynx Squ... Larynx Squamous... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Wake Forest University Health Sciences | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients. | NCT03917524 | Oral Cavity Squ... | 20 Years - | Chang Gung Memorial Hospital | ||
| A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery | NCT05316688 | Oral Cavity Squ... Stage I Lip and... Stage II Lip an... Stage III Lip a... Stage IVA Lip a... | Near Infrared I... Therapeutic Con... Tozuleristide | 18 Years - | University of Washington | |
| Articulatory Adaptation Following Oral Cancer Treatment | NCT05876247 | Oral Cavity Squ... Speech Disorder... | Electromagnetic... | 18 Years - | University Medical Center Groningen | |
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | NCT02156180 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 90 Years | Queensland Centre of Excellence for Head and Neck Cancer | ||
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
